Literature DB >> 31883269

AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221.

Rowan M Thomson1, Keith M Furutani2, Theodor W Kaulich3, Firas Mourtada4, Mark J Rivard5, Christopher G Soares6, Françoise M Vanneste7, Christopher S Melhus8.   

Abstract

The American Association of Physicists in Medicine (AAPM) formed Task Group 221 (TG-221) to discuss a generalized commissioning process, quality management considerations, and clinical physics practice standards for ocular plaque brachytherapy. The purpose of this report is also, in part, to aid the clinician to implement recommendations of the AAPM TG-129 report, which placed emphasis on dosimetric considerations for ocular brachytherapy applicators used in the Collaborative Ocular Melanoma Study (COMS). This report is intended to assist medical physicists in establishing a new ocular brachytherapy program and, for existing programs, in reviewing and updating clinical practices. The report scope includes photon- and beta-emitting sources and source:applicator combinations. Dosimetric studies for photon and beta sources are reviewed to summarize the salient issues and provide references for additional study. The components of an ocular plaque brachytherapy quality management program are discussed, including radiation safety considerations, source calibration methodology, applicator commissioning, imaging quality assurance tests for treatment planning, treatment planning strategies, and treatment planning system commissioning. Finally, specific guidelines for commissioning an ocular plaque brachytherapy program, clinical physics practice standards in ocular plaque brachytherapy, and other areas reflecting the need for specialized treatment planning systems, measurement phantoms, and detectors (among other topics) to support the clinical practice of ocular brachytherapy are presented. Expected future advances and developments for ocular brachytherapy are discussed.
© 2019 American Association of Physicists in Medicine.

Entities:  

Keywords:  commissioning; ocular brachytherapy; plaque brachytherapy; quality management; treatment planning

Year:  2020        PMID: 31883269     DOI: 10.1002/mp.13996

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Modified Geometry of 106Ru Asymmetric Eye Plaques to Improve Dosimetric Calculations in Ophthalmic Brachytherapy.

Authors:  Héctor Miras; José Antonio Terrón; Alejandro Bertolet; Antonio Leal
Journal:  J Pers Med       Date:  2022-04-29

2.  Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Cureus       Date:  2021-06-28

3.  Optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques: A simulation study based on current clinical practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  J Appl Clin Med Phys       Date:  2020-07-12       Impact factor: 2.102

4.  106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma.

Authors:  Ping Jiang; Konstantine Purtskhvanidze; Gerit Kandzia; Dirk Neumann; Ulf Luetzen; Frank-André Siebert; Johann Roider; Juergen Dunst
Journal:  Radiat Oncol       Date:  2020-07-29       Impact factor: 3.481

5.  Monte Carlo simulation of tilted contact plaque brachytherapy placement for juxtapapillary retinoblastoma.

Authors:  Satoshi Nakamura; Naoya Murakami; Shigenobu Suzuki; Kimiteru Ito; Mihiro Takemori; Hiroki Nakayama; Keita Kaga; Takahito Chiba; Kotaro Iijima; Kana Takahashi; Tomonori Goka; Jun Itami; Hiroyuki Okamoto; Hiroshi Igaki
Journal:  Radiat Oncol       Date:  2022-01-24       Impact factor: 3.481

6.  Outpatient ocular brachytherapy: The USC Experience.

Authors:  Sarah Joh; Mary E Kim; Michael Reilly; Sue Y Zhou; Jonathan Kim; Richard L Jennelle; Jesse L Berry
Journal:  Adv Radiat Oncol       Date:  2021-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.